Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an update.
Recordati S.p.A. reported strong financial results for 2024, with net revenues of €2,341.6 million, a 12.4% increase from the previous year, driven by growth in both specialty and primary care and rare diseases segments. The company proposed a dividend of €1.27 per share and reaffirmed its commitment to ESG objectives, including reducing emissions and enhancing sustainability practices, which are recognized by major ESG indices and ratings.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. operates in the pharmaceutical industry, focusing on specialty and primary care as well as rare diseases. The company is committed to developing new drugs and indications, particularly for rare diseases, and emphasizes sustainability and ESG initiatives.
YTD Price Performance: 5.43%
Average Trading Volume: 34,834
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €10.88B
For a thorough assessment of REC stock, go to TipRanks’ Stock Analysis page.